In a nutshell This study aimed to investigate the outcome of early switching from imatinib to dasatinib of patients with chronic-phase chronic myeloid leukemia with weak responses to imatinib treatment. The study concluded that this switch may offer clinical benefit in certain patients. Some background Imatinib...
Read MoreCurrent treatment status-Undergoing active treatment-No response Posts on Medivizor
How effective and safe is high-dose chemotherapy and stem cell transplant for children with lymphoma?
In a nutshell This study examined the effectiveness and safety of high-dose chemotherapy and stem cell transplants for children with lymphoma. The study showed that the combination treatment was very effective but that the dose may need to be adjusted for some patients. Some background Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) have very...
Read MoreEvaluating brentuximab vedotin for elderly patients with hard to treat Hodgkin lymphoma
In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) in elderly patients with relapsed or unresponsive Hodgkin lymphoma (HL). This study found that this treatment was effective, although frail patients may be at higher risk for side effects. Some background Most patients with HL respond to front-line...
Read MoreReviewing treatment options for patients with recurrent classical Hodgkin’s lymphoma
In a nutshell This article reviews treatment options for patients with classical Hodgkin's lymphoma (cHL) that came back (relapsed) after chemotherapy. This study found that targeted therapies are becoming more prevalent and that patient outcomes have improved. Some background cHL is a cancer of white blood cells called lymphocytes....
Read MoreHave outcomes improved for patients with Hodgkin’s lymphoma who relapse after a stem cell transplant?
In a nutshell This study evaluated the long-term outcomes of patients with classical Hodgkin’s lymphoma (cHL) that came back after an autologous stem cell transplant (autoSCT). This study found that advancements in treatment have helped improve survival outcomes for patients. Some background Chemotherapy is usually the first-line...
Read MoreThe comparison of outcomes of two salvage therapies in patients with relapsed or unresponsive acute myeloid leukemia
In a nutshell The study evaluated the effectiveness of two salvage therapies – mitoxantrone (Novantrone), etoposide (Etopophos), and cytarabine (Cytosar-U) also known as MEC and cladribine (Leustatin), cytarabine, filgrastim (Neupogen), and mitoxantrone also known as CLAG-M, for treating relapsed/refractory acute myeloid leukemia...
Read MoreEvaluating BEB chemotherapy for patients with non-Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of BEB (busulfan, etoposide, bendamustine) chemotherapy for patients with non-Hodgkin’s lymphoma (NHL). This study found that BEB chemotherapy was effective and well-tolerated in these patients. Some background Autologous stem cell transplantation (ASCT) is a standard...
Read MoreIbrutinib as a salvage treatment after transplant for patients with chronic lymphocytic leukemia
In a nutshell This study aimed to investigate if ibrutinib was safe and effective as a salvage treatment after stem cell transplant in patients with chronic lymphocytic leukemia. This study concluded that ibrutinib is safe and effective as a salvage treatment in these patients. Some background Allogeneic...
Read MoreEvaluating stem cell transplant outcomes for patients classical Hodgkin’s lymphoma
In a nutshell This study looked at the outcomes of autologous stem cell transplantation (ASCT) to treat recurrent classical Hodgkin’s lymphoma (cHL). This study concluded that ASCT is effective, with patients who responded after the transplant having the best outcomes. Some background cHL is usually treated with chemotherapy and...
Read MoreEvaluating BEGEV chemotherapy before a stem cell transplant for hard-to-treat Hodgkin lymphoma
In a nutshell This study evaluated the effectiveness of BEGEV chemotherapy for patients with relapsed or unresponsive Hodgkin lymphoma (HL) before a stem cell transplant. The authors concluded that this regimen was safe and effective for these patients. Some background Chemotherapy, followed by a stem cell transplant (SCT), remains the standard of...
Read MoreEvaluating long-term treatment with copanlisib for B-cell lymphoma
In a nutshell This looked at the safety and effectiveness of copanlisib (Aliqopa) for B-cell lymphoma that returned after previous treatment. This study found that long-term copanlisib treatment was safe and effective. Some background Indolent (painless) B-cell lymphoma is a slow-growing blood cancer. B-cell lymphoma that comes back or...
Read MoreEvaluating the combination of brentuximab vedotin and bendamustine in hard to treat Hodgkin lymphoma.
In a nutshell This study examined the safety and effectiveness of combining brentuximab vedotin (Adcetris) and bendamustine (Treanda) in patients with reoccurring or unresponsive Hodgkin lymphoma (HL). The authors concluded that this regimen shows promise in HL which is difficult to treat. Some...
Read More
